Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

Data from a new cyclophilin inhibitor

The degree of STG-175 antiviral efficacy was HCV > HIV-1 > HBV.
The addition of STG-175 together with virus totally blocked HCV and HIV-1
infection and greatly attenuated HBV infection. When added
3 days post-infection and then every 3 days, STG-175 totally
eradicated the pre-established HCV infection, almost totally
aborted the established HIV-1 infection and prevented the viral
expansion of the pre-established HBV infection.